The FDA is reviewing a possible link between the asthma drug Xolair and an increased risk of heart and cerebrovascular disorders.Since the FDA investigation is still under way, the agency is not telling doctors to stop prescribing Xolair and is not recommending any changes to the prescribing information for Xolair.
More...
The Food and Drug Administration Monday unveiled the details of a new policy designed to make...
As marijuana use among teens has grown in the past decade, researchers have been trying to...
NYU Langone Health, one of New York City’s major hospital networks, announced this week that it...
